Skin care company Crown Aesthetics reported on Wednesday the receipt of Medical Device Single Audit Programme (MDSAP) certification upon a rigorous audit by BSI (British Standards Institute).
Following MDSAP certification, the company will continue selling SkinPen, the first FDA cleared microneedling device, in Canada, Australia, Brazil and Japan.
MDSAP allows a single regulatory audit of a medical device manufacturer's quality management system to satisfy the requirements of multiple regulatory authorities. It covers the requirements of ISO 13485:2016 plus Good Manufacturing Practices (GMP) for each applicable regulatory authority. MDSAP is validation of the company's world-class service and pursuit of quality, safety and efficiency.
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML
Ligand Pharmaceuticals announces presentation of Captisol-enabled Topiramate Injection data